The CASP8 Knockout NCI-H1299 Polyclonal Cells represent a validated CRISPR/Cas9-mediated gene disruption model, produced as a polyclonal population of NCI-H1299 non-small cell lung carcinoma cells bearing targeted loss-of-function edits in the CASP8 locus. This heterogeneous pool of alleles ensures complete abrogation of caspase-8 protein function, enabling rigorous dissection of pathways that depend on its activity. As a polyclonal knockout product, the cells provide a robust platform for investigating death receptor-mediated signaling in a human lung adenocarcinoma background without the confounding effects of wild-type caspase-8 expression.
The parental NCI-H1299 cell line is derived from a metastatic non-small cell lung carcinoma (NSCLC) and represents an epithelial model of lung adenocarcinoma. These cells are characterized by a homozygous deletion of TP53 (p53-null) and harbor wild-type KRAS and EGFR genes. NCI-H1299 cells are extensively employed in cancer research to examine apoptosis regulation, metastatic potential, and mechanisms of drug resistance, particularly in the context of p53-deficient tumor biology.
CASP8 encodes caspase-8, an initiator caspase central to the extrinsic apoptosis cascade. Upon ligation of death receptors such as FAS, TNFR1, or TRAIL receptors (DR4/DR5), caspase-8 is recruited to death-inducing signaling complexes (DISCs) via adaptor FADD, where it undergoes dimerization and activation. Active caspase-8 proteolytically processes downstream executioner caspases (CASP3, CASP7) and the BH3-only protein BID to truncated tBID, linking extrinsic and intrinsic apoptotic pathways. Caspase-8 also intersects with necroptosis and inflammation; it cleaves and inactivates RIPK1 under apoptotic conditions, while its inhibition or absence permits RIPK1-mediated necroptotic signaling. Key regulatory interactions include binding with c-FLIP, which modulates caspase-8 activity, and association with TRAF2 and cIAPs in TNF signaling complexes. Knockout of CASP8 abrogates receptor-mediated apoptosis, potentially shifting cellular death toward necroptosis and altering NF-??B and toll-like receptor inflammatory signaling.
In the NCI-H1299 background, caspase-8 disruption has profound consequences for cell death fate decisions. The absence of p53 already compromises intrinsic apoptotic pathways, and combined caspase-8 deficiency renders these cells highly resistant to death receptor-induced apoptosis. This creates a model system uniquely suited to explore alternative cell death modalities, such as TNF-alpha-induced necroptosis mediated by RIPK1 and MLKL. Furthermore, caspase-8??s non-apoptotic roles in inflammation and immune signaling can be studied in a cancer context, facilitating research into how lung adenocarcinoma cells evade immune surveillance and develop metastatic capacity when apoptosis is suppressed.
These polyclonal knockout cells enable delineation of apoptosis-independent cell death mechanisms, particularly necroptosis, through LDH release and RIPK1 phosphorylation analysis. They are suitable for synthetic lethality screens to identify vulnerabilities in caspase-8-null tumors, as well as immune evasion studies using co-culture systems and cytokine profiling. Standard assays include western blotting for caspase-8, Annexin V/PI flow cytometry, TRAIL/FasL sensitivity testing, and migration/invasion assays paired with RNA-seq. For further details, please contact Ascent Research.
